Proton Therapy Fails to Improve Survival in Advanced Liver Cancer Patients

Initial findings from a major clinical trial suggest that proton therapy does not improve survival rates for patients with advanced hepatocellular carcinoma (HCC), a common form of liver cancer. The NRG Oncology NRG-GI003 study compared proton therapy with traditional photon therapy, but early results showed no significant difference in overall survival between the two approaches.

The trial was halted at an interim analysis after data crossed a pre-defined futility boundary, indicating that proton therapy was unlikely to provide meaningful benefits. Researchers also found no improvements in secondary outcomes, such as progression-free survival or the likelihood of cancer spreading locally.

These results challenge the assumption that proton therapy, which is more expensive and less widely available, offers superior outcomes for certain cancers. The study reinforces the current standard of care for advanced HCC, which typically involves photon-based treatments and other systemic therapies.

Further analysis of the trial’s long-term data is ongoing, and researchers emphasize the need for more studies to explore potential differences in patient subgroups or long-term side effects. For now, the findings suggest that proton therapy may not be a better option for advanced HCC.

Based on reporting from Medical Xpress (Cancer).

Source: Medical Xpress (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.